Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugsthat are safer, easier for patients to tolerate and more effective.
Industry sector: Medical
Sector classification: Biological products, except diagnostic
Deep Learning based analysis and prediction model for Gilead Sciences, Inc. (GILD) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 23, 2015.
Market data for GILD model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
|% Held by Insiders||1.30%|
|% Held by Institutions||74.02%|
|EPS (last reported FY)||$11.37|
|EPS (last reported Q)||$2.51|
|EPS, estimated (last reported Q)||$2.11|
|Total revenues||$30 B|
|Net income||$14 B|